Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2022-01-14 00:00:00 ET · period of report 2022-01-13 · accession 0001209191-22-003402 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-01-14 | 2022-01-13+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +341.0K | 277.5K | New | $0 |
| DM | 2022-01-14 | 2022-01-13+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $13.76 | -341.0K | 23.5K | -94% | -$4.69M |
| DM | 2022-01-14 | 2022-01-13+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -341.0K | 8.03M | -4% | $0 |
| D | 2022-01-14 | 2021-12-28 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -75.0K | 8.12M | -0.9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-01-13 | C | A | 87,000 | $0.00 | 110,470 | D | — | — | |
| 2 | Common | Class A Common Stock | 2022-01-13 | S | D | 78,206 | $14.26 | 32,264 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $13.80 to $14.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2022-01-14 | S | D | 254,000 | $13.57 | 23,470 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $13.09 to $14.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Common | Class A Common Stock | 2022-01-14 | C | A | 254,000 | $0.00 | 277,470 | D | — | — | |
| 5 | Common | Class A Common Stock | 2022-01-13 | S | D | 8,794 | $14.96 | 23,470 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $14.80 to $15.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 6 | Derivative | Class B Common Stock | 2022-01-14 | C | D | 254,000 | $0.00 | 7,778,342 | D | $0.00 · — to — | 254,000 Class A Common Stock | (F6) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |
| 7 | Derivative | Class B Common Stock | 2022-01-13 | C | D | 87,000 | $0.00 | 8,032,342 | D | $0.00 · — to — | 87,000 Class A Common Stock | (F6) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |
| 8 | Derivative | Class B Common Stock | 2021-12-28 | G | D | 75,000 | $0.00 | 8,119,342 | D | $0.00 · — to — | 75,000 Class A Common Stock | (F6) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |